The concern of generic rivalry has consistently loomed around copyright’s blockbuster drug, PDE5 Inhibitor, triggering questions about the prospects of related pharmaceutical holdings. While first years saw substantial profits, the patent expiration has created the path for less expensive copies, likely diminishing revenue and posing a real dange